A potential event-competition bias in safety signal detection: Results from a spontaneous reporting research database in France

Drug Safety

Volumn 36, Issue 7, 2013, Pages 565-572

  Salvo, Francesco ^a,b   Leborgne, Florent ^a   Thiessard, Frantz ^a,c   Moore, Nicholas ^a,c   Bégaud, Bernard ^a,c   Pariente, Antoine ^a,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIRETROVIRUS AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; BLEEDING; DATA BASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EXTRAPYRAMIDAL SYNDROME; FRANCE; LIPODYSTROPHY; MYOPATHY; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIGNAL DETECTION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-RETROVIRAL AGENTS; ANTICOAGULANTS; ANTIPSYCHOTIC AGENTS; DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FRANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 84879896592     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0063-5     Document Type: Article

References (52)

1. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21):1520-8 (2 p following 8).
2. Weill A, Paita M, Tuppin P, Fagot JP, Neumann A, Simon D, et al. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf. 2010;19(12):1256-62.
3. Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf. 2003;26(3):159-86.
4. Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf. 2011;20(7):772-7.
5. Moore N, Thiessard F, Begaud B. The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf. 2005;14(4):285-6.
6. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf. 1994;10(2):93-102.
7. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315-21.
8. Dumouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53(3):177-90.
9. Waller P, van Puijenbroek E, Egberts A, Evans S. The reporting odds ratio versus the proportional reporting ratio: 'deuce'. Pharmacoepidemiol Drug Saf. 2004;13(8):525-6 (discussion 7-8).
10. Roux E, Thiessard F, Fourrier A, Begaud B, Tubert-Bitter P. Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance. IEEE Trans Infect Technol Biomed. 2005;9(4):518-27.
11. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3-10.
12. Pariente A, Avillach P, Salvo F, Thiessard F, Miremont-Salame G, Fourrier-Reglat A, et al. Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France. Drug Saf. 2012;35(10):855-64.
13. Gould AL. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf. 2003;12(7):559-74.
14. Wang HW, Hochberg AM, Pearson RK, Hauben M. An experimental investigation of masking in the US FDA adverse event reporting system database. Drug Saf. 2010;33(12):1117-33.
15. Pariente A, Didailler M, Avillach P, Miremont-Salame G, Fourrier-Reglat A, Haramburu F, et al. A potential competition bias in the detection of safety signals from spontaneous reporting databases. Pharmacoepidemiol Drug Saf. 2010;19(11):1166-71.
16. Thiessard F, Roux E, Miremont-Salame G, Fourrier-Reglat A, Haramburu F, Tubert-Bitter P, et al. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001). Drug Saf. 2005;28(8):731-40.
17. Conforti A, Chiamulera C, Moretti U, Colcera S, Fumagalli G, Leone R. Musculoskeletal adverse drug reactions: a review of literature and data from ADR spontaneous reporting databases. Curr Drug Saf. 2007;2(1):47-63.
18. Tiaden JD, Wenzel E, Berthold HK, Muller-Oerlinghausen B. Adverse reactions to anticoagulants and to antiplatelet drugs recorded by the German spontaneous reporting system. Semin Thromb Hemost. 2005;31(4):371-80.
19. Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Fortuna P, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr. 2000;23(3):236-45.
20. Biswasl PN, Wilton LV, Pearcel GL, Freemantle S, Shakir SA. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol. 2001;15(4):265-71.
21. MMSSO. Introductory Guide MedDRA Version 14.0. Chantilly, Virginia2011. http://www.meddramsso.com/files-acrobat/intguide-14-0-English-update.pdf.
22. Moore N, Kreft-Jais C, Haramburu F, Noblet C, Andrejak M, Ollagnier M, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol. 1997;44(5):513-8.
23. Pearson RK, Hauben M, Goldsmith DI, Gould AL, Madigan D, O'Hara DJ, et al. Influence of the MedDRA hierarchy on pharmacovigilance data mining results. Int J Med Inform. 2009;78(12):e97-103.
24. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373-418.
25. Horiuchi Y, Maruoka H. Petechial eruptions due to simvastatin in a patient with diabetes mellitus and liver cirrhosis. J Dermatol. 1997;24(8):549-51.
26. Koduri PR. Simvastatin and thrombotic thrombocytopenic purpura. Lancet. 1998;352(9145):2020.
27. McCarthy LJ, Porcu P, Fausel CA, Sweeney CJ, Danielson CF. Thrombotic thrombocytopenic purpura and simvastatin. Lancet. 1998;352(9136):1284-5.
28. Possamai G, Bovo P, Santonastaso M. Thrombocytopenic purpura during therapy with simvastatin. Haematologica. 1992;77(4):357-8.
29. Ahmad S. Lovastatin. Warfarin interaction. Arch Intern Med. 1990;150(11):2407.
30. Iliadis EA, Konwinski MF. Lovastatin during warfarin therapy resulting in bleeding. Pa Med. 1995;98(12):31.
31. Haroon M, Devlin J. A case of ANCA-associated systemic vasculitis induced by atorvastatin. Clin Rheumatol. 2008;27(Suppl 2):S75-7.
32. Roberto G, Biagi C, Montanaro N, Koci A, Moretti U, Motola D. Statin-associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature. Eur J Clin Pharmacol. 2012;68:1007-11.
33. Ehrenforth S, Schenk JF, Scharrer I. Liver damage induced by coumarin anticoagulants. Semin Thromb Hemost. 1999;25(1):79-83.
34. Hohler T, Schnutgen M, Helmreich-Becker I, Mayet WJ, Mayer zum Buschenfelde KH. Drug-induced hepatitis: a rare complication of oral anticoagulants. J Hepatol. 1994;21(3):447-9.
35. Howitt AJ, Williams AJ, Skinner C. Warfarin-induced vasculitis: a dose-related phenomenon in susceptible individuals? Postgrad Med J. 1982;58(678):233-4.
36. Stavorovsky M, Lichtenstein D, Nissim F. Skin petechiae and ecchymoses (vasculitis) due to anticoagulant therapy. Dermatologica. 1979;158(6):451-61.
37. Tanay A, Yust I, Brenner S, Koffler M, Abramov AL. Dermal vasculitis due to coumadin hypersensitivity. Dermatologica. 1982;165(3):178-85.
38. Nakamizo S, Egawa G, Arakawa A, Miyachi Y, Kabashima K. Warfarin-induced alopecia after repeated chemotherapy. Eur J Dermatol. 2010;20(6):828-9.
39. Umlas J, Harken DE. Warfarin-induced alopecia. Cutis. 1988;42(1):63-4.
40. Ho CK, Kaufman RL, McAlister WH. Congenital malformations. Cleft palate, congenital heart disease, absent tibiae, and polydactyly. Am J Dis Child. 1975;129(6):714-6.
41. Coppola D, Russo LJ, Kwarta RF Jr, Varughese R, Schmider J. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf. 2007;30(3):247-64.
42. Cherry CL, McArthur JC, Hoy JF, Wesselingh SL. Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol. 2003;26(2):195-207.
43. Gerstoft J, Kirk O, Obel N, Pedersen C, Mathiesen L, Nielsen H, et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS. 2003;17(14):2045-52.
44. Pettersen JA, Jones G, Worthington C, Krentz HB, Keppler OT, Hoke A, et al. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol. 2006;59(5):816-24.
45. Spruance SL, Pavia AT, Mellors JW, Murphy R, Gathe J Jr, Stool E, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med. 1997;126(5):355-63.
46. Centers for Disease Control and Prevention. Birth outcomes following zidovudine therapy in pregnant women. MMWR Morb Mortal Wkly Rep. 1994;43(22):409, 415-6.
47. White A, Eldridge R, Andrews E. Birth outcomes following zidovudine exposure in pregnant women: the Antiretroviral Pregnancy Registry. Acta Paediatr Suppl. 1997;421:86-8.
48. Birth defect rates unchanged by antiretrovirals. AIDS Patient Care STDS. 2007;21(6):436.
49. Thorne C, Newell ML. The safety of antiretroviral drugs in pregnancy. Expert Opin Drug Saf. 2005;4(2):323-35.
50. Guaraldi G, Ventura P, Albuzza M, Orlando G, Bedini A, Amorico G, et al. Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy. AIDS. 2001;15(1):137-8.
51. Torti C, Mazziotti G, Soldini PA, Foca E, Maroldi R, Gotti D, et al. High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine. 2012;41(3):512-7.
52. Pariente A, Daveluy A, Laribiere-Benard A, Miremont-Salame G, Begaud B, Moore N. Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA. Drug Saf. 2009;32(5):441-7.